Novo nabs anti-infectives outfit in $700M buyout

Turns out there was some truth behind the rumors that 3i was shopping the anti-infectives company Xellia. Novo picked up all the shares in the company for $700 million, significantly less than the $974 million figure Reuters heard about in late April. 3i created Xellia from a management spinout from Alpharma back in 2008. In the last 5 years Xellia has grown from an active pharmaceutical ingredient manufacturer to a developer and marketer of anti-infectives, with facilities in Denmark, Norway, Hungary and China. Release


Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.